The company utilizes a platform to assess the impact of RNA-modifying proteins on disease biology and generates a pipeline of small molecules targeting priority cancer targets. Founded in 2019 by a team with a successful track record in pharma and biotech drug discovery, 858 Therapeutics specializes in the fields of innate immunity, synthetic lethality, and RNA modulation. Headquartered in San Diego, California, the company is dedicated to advancing its portfolio of small molecule drugs for oncology.